AKR1C3 and cancer: Thus, for adjuvant therapy, AKR1C3 inhibitors do not necessarily have to be cytotoxic to cancer cells on their own; but instead would ideally prevent metabolism and improve the cytotoxic and antiproliferative activity of other anti-cancer drugs.